C4 Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
About C4 Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
This clinical-stage biopharmaceutical company focuses on developing targeted protein degradation therapies to address unmet medical needs. Utilizing its proprietary TORPEDO platform, the company creates orally bioavailable small-molecule medicines designed to destroy disease-causing proteins via natural cellular processes. Its clinical pipeline features cemsidomide, a molecular glue degrader being evaluated for multiple myeloma, and CFT8919, an allosteric degrader targeting non-small cell lung cancer with specific genetic mutations. The company also advances early-stage discovery programs directed at inflammation, neuroinflammation, and neurodegenerative conditions, serving patient populations facing severe oncologic and neurological disorders.
The company conducts clinical trials and research activities across multiple territories, with clinical development of CFT8919 underway in Greater China through a partnership, while maintaining development rights for other global regions. Additionally, it engages in collaborative research and licensing alliances with major pharmaceutical partners, including Merck KGaA and Roche. The provided text does not state the location of the company's headquarters.
Summary of the business section of C4 Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- C4 Therapeutics, Inc.
- Founded
- 2015
- Headquarters
- Watertown, MA
- Address
- 490 Arsenal Way, Suite 120 02472
- Phone
- (617) 231-0700
- Website
- c4therapeutics.com
- Employees
- 104, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, MA, United States
Stock & identifiers
- Ticker
- CCCC
- Exchange
- Nasdaq
- IPO date
- Oct 2, 2020
- Shares outstanding
- 123M, Jul 31, 2026
- Public float
- $100.05M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1662579
- CUSIP
- 12529R107
- ISIN
- US12529R1077
- EIN
- 47-5617627
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew Hirsch | President & CEO, Director | 1,083,991 |
| Kendra Adams | Chief Financial Officer | 385,098 |
| Leonard Reyno | Chief Medical Officer | 372,406 |
| Kelly Schick | Chief People Officer | 299,881 |
| Mark Mossler | Chief Accounting Officer | 71,916 |
| Paige Mahaney | Chief Scientific Officer | 336,910 |
| Scott N. Boyle | Chief Business Officer | 306,070 |
| Jolie Siegel | Chief Legal Officer | 107,939 |
| Kenneth Carl Anderson | Director | 358,235 |
| Donna Roy Grogan | Director | 74,853 |
| Owen Hughes | Director | – |
| Utpal Koppikar | Director | 5,667 |
| Steven L. Hoerter | Director | – |
| Laura Bessen | Director | – |
| Ronald Harold Wilfred Cooper | Director | – |
| Stephen Fawell | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Hirsch | $2.94M | $1.32M | $1.56M | $32 | – |
| FY2024 Mr. Hirsch | $4.63M | $905.03K | $2.29M | $61 | – |
| FY2023 Mr. Hirsch | $3.79M | $4.34M | $1.60M | $96 | – |
| FY2022 Mr. Hirsch | $2.60M | -$21.61M | $3.51M | $18 | – |
| FY2021 Mr. Hirsch | $952.20K | -$79.71K | $3.94M | $97 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 104 full-time employees, including 40 employees with an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 2, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 28, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |